We analyzed data from the OPTIME-CHF ( Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure ) study , a randomized trial of intravenous milrinone versus placebo in 949 patients hospitalized with ADHF .
